13 Nov 2017 07:15
Hardman Research: Streamlined and clean
Streamlined and clean - Redx has emerged from administration with a refocused R&D pipeline and in a very clean financial state with £13.6m net cash in the bank. The group's strategy has been validated by the successful disposal of its pre-clinical programme BTK for $40m. The new Board & Management team will focus resources on the early clinical development of its next two lead candidates, in oncology and fibrotic disease, which are expected to start Phase I trials in 2018 and 2019, respectively. There was an inevitable knee-jerk reaction when the shares were re-quoted but consideration should be given to the potential value within the focused pipeline.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/redx-pharma--documents/13.11.17-streamlined-and-clean.pdf
To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH Follow us on Twitter @HardmanandCo | Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave
+44 20 7194 7622 |
mh@hardmanandco.com dmh@hardmanandco.com gp@hardmanandco.com
hardman@hardmanandco.com |
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.